Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma

Part of paid clinical trials in New York, New York.

Sponsor
Herbert Irving Comprehensive Cancer Center
Study ID
NCT00003719
Phase
PHASE2
Status
Unknown

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have stage IV or recurrent soft tissue sarcoma that has been previously treated with chemotherapy.

Key Dates

Start date
Jul 31, 1997
Status verified
Aug 2001

Study Design

Enrollment
27 participants (estimated)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Herbert Irving Comprehensive Cancer CenterNew YorkNew York10032-

Find similar trials in New York, NY

By research site
Herbert Irving Comprehensive Cancer Center· New York, NY

Related Studies